Pharmacovigilance: Ensuring Safety and Efficacy in Therapeutic Interventions

Maya Al-Farouqi*

Department of Clinical Pharmacology, Gulf Medical University, Abu Dhabi, United Arab Emirates

*Author for Correspondence:
maya.alfarouqi@gmu.ac.ae

Introduction

Pharmacovigilance is the science and activities focused on detecting, assessing, understanding, and preventing adverse effects or any other drug-related problems. It plays a crucial role in ensuring the safety, efficacy, and quality of medicines throughout their lifecycle. With the increasing complexity of therapeutic agents, including biologics, targeted therapies, and combination regimens, pharmacovigilance has become an essential component of modern healthcare systems and regulatory frameworks.

Objectives and Importance

The primary objective of pharmacovigilance is to safeguard public health by identifying adverse drug reactions (ADRs) and minimizing risks associated with drug therapy. It also supports informed decision-making for clinicians, regulatory authorities, and patients. Effective pharmacovigilance contributes to the optimization of therapeutic outcomes, early detection of rare or severe adverse events, and continuous improvement of treatment guidelines.

Methods and Tools

Pharmacovigilance relies on both passive and active surveillance systems. Passive reporting involves spontaneous ADR reports submitted by healthcare professionals and patients to national or global databases, such as the WHO's VigiBase. Active surveillance includes cohort event monitoring, registries, and post-marketing clinical studies designed to systematically capture adverse events.

Advances in digital health, electronic health records, and data analytics have enhanced the ability to detect safety signals rapidly. Machine learning and artificial intelligence are increasingly used to analyze large datasets and predict potential drug-related risks.

Clinical Applications

In clinical practice, pharmacovigilance informs risk-benefit assessments for individual patients, guiding treatment modifications or discontinuation when necessary. It is particularly vital for high-risk populations, such as the elderly, pregnant women, or patients with comorbidities. Post-marketing surveillance ensures that rare, delayed, or cumulative adverse effects are identified, complementing pre-approval clinical trial data.

Conclusion

Pharmacovigilance is a cornerstone of patient safety and responsible therapeutic practice. By systematically monitoring, analyzing, and responding to adverse drug events, it protects public health, informs clinical decision-making, and enhances confidence in modern therapies. Continuous innovation in surveillance methods and data analysis promises to strengthen pharmacovigilance and support safer, more effective healthcare delivery worldwide.